Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
26 hedge funds and large institutions have $372K invested in Agile Therapeutics in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 6 closing their positions.
0% more funds holding
Funds holding: 26 → 26 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
46% less capital invested
Capital invested by funds: $683K → $372K (-$311K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$33.2K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.16K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.36K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$3.08K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$158K |
| 2 |
Millennium Management
New York
|
-$30K |
| 3 |
Renaissance Technologies
New York
|
-$29.7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$12.8K |
| 5 |
Jane Street
New York
|
-$5.7K |
AGRX Hedge Fund Activity: Q4 2022 in Review
26 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q4 2022, worth a combined $372K — down 46% from $683K a quarter earlier.
Fund positioning in AGRX was balanced in Q4 2022: 6 funds opened new positions, 6 closed out, 5 added to existing stakes and 8 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $33.2K. The largest seller was Perceptive Advisors, exiting entirely with an estimated $158K sold.
- 26 institutional investors held Agile Therapeutics (AGRX) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $372K of Agile Therapeutics stock for Q4 2022, down 46% quarter-over-quarter.
- 6 funds opened new Agile Therapeutics positions in Q4 2022 and 6 closed out, a net change of 0 holders.
- The largest Agile Therapeutics buyer in Q4 2022 was Virtu Financial, an estimated $33.2K added.
- The largest Agile Therapeutics seller in Q4 2022 was Perceptive Advisors, an estimated $158K sold.
Based on aggregated 13F filings for Q4 2022.